Invitrocue Limited

Invitrocue Limited engages in the research and experimental development on biotechnology, life, and medical science primarily in Singapore, Australia, China, Hong Kong, and Germany. The company develops Onco Patient-Derived Organoid (PDO) test, a personalized cancer treatment for cancer patients; and 3D CelluSponge series, a 3D in-vitro platform technology for various applications, including 3D cell culture, hepatocyte culture, in-vitro drug metabolism and pharmacokinetics assays and toxicology, stem cell differentiation, PDO, and pathogen infection and detection. It also provides respiratory disease, and customized assays and disease modelling services. Invitrocue Limited was founded in 2012 and is headquartered in Singapore.